The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

Marzia Del ReEleonora RofiCarla CappelliGianfranco PuppoStefania CrucittaSimona ValeggiAntonio ChellaRomano DanesiIacopo Petrini

Published in: BMC cancer (2019)

The measurement of ex19del changes in ctDNA is a simple and sensitive approach to monitor clinical outcome to osimertinib and, potentially, to other therapeutic interventions.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
signaling pathway
physical activity
circulating tumor